Merck Signs a Research Collaboration and Commercial License Agreement with Mersana for Novel Antibody-Drug Conjugates
Shots:
- Mersana will receive $30M up front & is also eligible to receive reimbursement of certain costs, ~$800M in regulatory, development & commercial milestones along with royalties on net sales of any approved ADCs
- Mersana will develop novel ADC product candidates against ~2 targets using the Immunosynthen STING-agonist platform to conjugate proprietary Abs. Merck KGaA will lead the clinical development & commercialization activities relating to any resulting product candidates
- The collaboration complements Merck’s expertise & in-house ADC approach. Preclinical data produced by Mersana showed Immunosynthen's capacity to enable highly targeted STING activation within tumor cells & tumor resident myeloid cells while avoiding unfavorable systemic effects
Ref: Businesswire | Image: Merck kgaA
Related Posts:- Merck KGaA Entered into Option to License Agreement with Nerviano Medical Sciences to Develop NMS-293
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
